PTLA—Depending on the post-IPO valuation, I might be tempted. If the FXa reverser works well, I could see PFE (or BMY) buying the whole company. (An acquirer would shut down the betrixaban program, of course.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”